Humacyte (NASDAQ:HUMA) Lowered to “Strong Sell” Rating by Wall Street Zen

Humacyte (NASDAQ:HUMA) was downgraded by research analysts at Wall Street Zen from a “sell” rating to a “strong sell” rating in a report released on Sunday.

A number of other brokerages also recently commented on HUMA. TD Cowen lowered their price target on shares of Humacyte from $1.50 to $1.25 and set a “buy” rating for the company in a report on Wednesday, June 17th. Benchmark raised their price objective on Humacyte to $2.00 and gave the company a “speculative buy” rating in a research note on Monday, June 1st. D. Boral Capital reiterated a “buy” rating and issued a $25.00 target price on shares of Humacyte in a report on Tuesday, April 28th. HC Wainwright boosted their target price on Humacyte from $3.00 to $4.00 and gave the company a “buy” rating in a research report on Thursday, June 11th. Finally, BTIG Research restated a “buy” rating and set a $2.00 price target on shares of Humacyte in a report on Tuesday, June 16th. Seven analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Humacyte currently has an average rating of “Moderate Buy” and a consensus price target of $6.25.

Humacyte Price Performance

Humacyte stock traded down $0.01 during mid-day trading on Friday, reaching $0.69. 13,040,602 shares of the company’s stock traded hands, compared to its average volume of 16,760,806. The company has a market cap of $154.02 million, a price-to-earnings ratio of -1.22 and a beta of 2.52. The stock has a 50 day moving average of $0.99 and a two-hundred day moving average of $0.97. The company has a quick ratio of 3.32, a current ratio of 3.93 and a debt-to-equity ratio of 5.46. Humacyte has a 12-month low of $0.55 and a 12-month high of $2.84.

Humacyte (NASDAQ:HUMA) last released its quarterly earnings data on Wednesday, May 13th. The company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.10) by $0.01. Humacyte had a negative net margin of 4,836.06% and a negative return on equity of 2,914.18%. The business had revenue of $0.49 million during the quarter, compared to analyst estimates of $1.46 million. Equities analysts forecast that Humacyte will post -0.34 earnings per share for the current year.

Insiders Place Their Bets

In other Humacyte news, insider Shamik J. Parikh sold 45,887 shares of the business’s stock in a transaction that occurred on Monday, May 18th. The stock was sold at an average price of $0.90, for a total transaction of $41,298.30. Following the completion of the transaction, the insider owned 272,713 shares in the company, valued at $245,441.70. The trade was a 14.40% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Kathleen Sebelius bought 56,818 shares of the company’s stock in a transaction on Tuesday, May 19th. The shares were acquired at an average price of $0.88 per share, with a total value of $49,999.84. Following the transaction, the director directly owned 148,025 shares of the company’s stock, valued at approximately $130,262. This trade represents a 62.30% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. 3.10% of the stock is owned by insiders.

Hedge Funds Weigh In On Humacyte

Hedge funds have recently bought and sold shares of the business. UBS Group AG grew its holdings in shares of Humacyte by 48.8% in the fourth quarter. UBS Group AG now owns 2,978,610 shares of the company’s stock worth $2,862,000 after purchasing an additional 976,275 shares during the last quarter. United Asset Strategies Inc. lifted its holdings in shares of Humacyte by 13.5% in the 4th quarter. United Asset Strategies Inc. now owns 209,608 shares of the company’s stock worth $201,000 after buying an additional 25,000 shares during the period. SG Americas Securities LLC grew its position in shares of Humacyte by 50.3% during the 4th quarter. SG Americas Securities LLC now owns 34,075 shares of the company’s stock worth $33,000 after buying an additional 11,411 shares in the last quarter. R Squared Ltd increased its stake in shares of Humacyte by 140.5% during the first quarter. R Squared Ltd now owns 62,911 shares of the company’s stock valued at $38,000 after buying an additional 36,758 shares during the period. Finally, Private Advisor Group LLC raised its holdings in shares of Humacyte by 48.3% in the first quarter. Private Advisor Group LLC now owns 832,799 shares of the company’s stock valued at $505,000 after acquiring an additional 271,222 shares in the last quarter. Institutional investors own 44.71% of the company’s stock.

Humacyte Company Profile

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.